

## **CURRICULUM VITAE**

**Brian Onbirbak, MD**

### **OFFICE:**

University Medical Center  
Wellness Center  
2300 S. Rancho Dr. Suite 205  
Las Vegas, NV 89102  
Tel (702) 383-2691  
Fax (702) 388-4114  
E-mail: [brian.onbirbak@umcsn.com](mailto:brian.onbirbak@umcsn.com)

### **HOSPITAL AFFILIATION:**

University Medical Center  
1800 West Charleston Boulevard  
Las Vegas, NV 89102  
(702) 383-2000

### **EDUCATION AND TRAINING**

Residency Program B, University of Nevada School of Medicine, Department of Internal Medicine, Las Vegas, NV, September 92-August 94

Residency Program A, University of Nevada School of Medicine, Department of Internal Medicine, Reno, NV, September 91-August 92

Doctor in Medicine, Escuela de Medicina, Universidad Tecnologica De Santiago (UTESA), Santo Domingo, Dominican Republic, June 1988

Bachelor of Science, Biology, San Diego State University, San Diego, California, January 1985

### **PROFESSIONAL EXPERIENCE**

Staff Physician, Ryan White Care Act Clinical Director, University Medical Center, HIV Wellness Center, 2300 S. Rancho Dr. #205, Las Vegas, Nevada, March 1997- Present

Acting Medical Director, University Medical Center, HIV Wellness Center, 1112 Shadow Lane, Las Vegas, Nevada, Oct. 1994- March 1997

Private Practice, Southwest Medical Associates, 2300 West Charleston Blvd., Suite 259, Las Vegas, Nevada, 1996-1997

Associate Clinical Professor of Medicine, Department of Internal Medicine, University of Nevada, School of Medicine, Nov. 1996-present

## **CURRICULUM VITAE**

Brian Onbirbak, MD

Page 2

Member, Physician Advisory Committee, Ryan White Title II AIDS Drug Assistance Program, State of Nevada, Nov. 1995-2000

Member, Nevada State Ryan White Title II planning council 1995-1996

Regional Consultant, Merck & Co. Inc., 1996- 1999, Agouron Pharmaceuticals Inc., 1997-Present, Glaxo Smithkline 1998-2000, Dupont Pharmaceuticals Inc., 1999, Bristol-Myers-Squibb 2000-present, Hoffman-LaRoche Ltd, 1997-present, Gilead Sciences 2002-present.

Faculty Speaker, Hoffman-LaRoche LTD, 1997 – 2000, Bristol-Myers Squibb, 1998 –present, Faculty Speaker, Glaxo Wellcome Inc., 1998 – 2000, Boehringer-Ingelheim 2001-present, Gilead Sciences 2002-present.

Medical Director, Southern Nevada Area Health Education and Training Center (AHEC), Nevada AIDS Education and Training Center (AETC), 1094 E Sahara Ave Las Vegas, NV, Las Vegas, Nevada, April 2004-present

Attending Physician, Quick Care Centers, University Medical Center, 1800 west Charleston Boulevard, Las Vegas, NV, Oct. 1994-95

Resident Physician, University of Nevada School of Medicine, Department of Internal Medicine, 2040 West Charleston Boulevard, Las Vegas, Nevada, Sept. 1991-Aug. 1994

Paramedical Reporter, Physical Measurements Information, Equifax Services Inc., San Diego, CA, July 88-Aug. 91

## **PROFESSIONAL CERTIFICATION AND LICENSURE**

Licensed Medical Doctor, States of Nevada and Arizona

FLEX - State of Nevada, Reno, Nevada, 1992

ECFMG Permanent Certification, Philadelphia, Pennsylvania, 1992

Member, American Academy of HIV Medicine

## **GRANTS**

Clinical Director Ryan White Grants for Primary Care Services for HIV Infected Individuals for HIV Wellness Center at University Medical Center of Southern Nevada, 1995 to Present.

Author, competing continuation of Ryan White Title III funding 2001 and 2003, supplemental Ryan White Title III Grant Program 1997, 1999 and 2001, and 2002, non-competing continuation 2004 and 2005, Wellness Center, Las Vegas, NV.

## **CURRICULUM VITAE**

Brian Onbirbak, MD

Page 3

## **RESEARCH**

CCR104627. A screening protocol to determine eligibility for one of three Phase III treatment studies evaluating the efficacy and safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 infected, treatment-experienced subjects with drug-resistant virus or an observational study in X4-tropic or non-phenotypeable HIV-1 infected, treatment-experienced subjects with drug-resistant virus. GlaxoSmithKline. July 2005.

CCR102881. A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults. GlaxoSmithKline. Investigator. March 2005.

ML18018D. A 12-week, prospective, open-label, multicenter, cohort study to assess HIV-patient quality of life and tolerability after administration of enfuvirtide-containing HAART (Qualite). Roche. Investigator. December 2004.

BI1182.70. An open label, non-randomized treatment protocol of tipranavir co-administered with low-dose ritonavir (TPV/r) in protease inhibitor-experienced patients with HIV-1 infection (the tipranavir expanded access program). Boehringer Ingelheim. Investigator. December 2004.

COL102060. An open-label, multicenter study to evaluate the efficacy and safety of a fixed-dose combination of abacavir 600mg/lamivudine 300mg once-daily in combination with atazanavir 300mg + ritonavir 100mg once-daily in antiretroviral-naïve HIV-1 infected subjects over 48 weeks. GlaxoSmithKline. Investigator. December 2004.

NN210005. A phase I, multicenter, randomized, parallel, double-blinded dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral dosage regimens of GW695634G monotherapy versus placebo over 7 days in NNRTI-experienced HIV-1 infected adults. GlaxoSmithKline. Investigator. July 2004

BI1182.58. An open label safety study to evaluate the safety of tipranavir plus ritonavir when used in combination with other agents for the treatment of patients with HIV infection who have failed and/or are intolerant to combination antiretroviral therapy and have limited treatment options. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator May 2003.

BI1182.51. An open label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimised background regimen, in multiple antiretroviral (ARV) experienced patients. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. Jan 2003.

BI1182.12. Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST-1: Randomized

## **CURRICULUM VITAE**

Brian Onbirbak, MD

Page 4

Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir). Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. Jan 2003.

MV16812. Multicenter, open-label, early access program of fuzeon (enfuvirtide T-20/Ro29-9800, HIV-1 Fusion Inhibitor) in combination with free choice antiretroviral regimen to assess serious adverse events, serious AIDS defining events, and tolerability in patients with advanced HIV-infection. F. Hoffmann-LaRoche LTD, Trimeris Inc., Investigator.

BI1182.17. A long term open label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir use in HIV-1 infected subjects. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator August 2002.

AI424900. Atazanavir (BMS-232632) for HIV infected individuals: An early access program. Bristol-Myers Squibb. Investigator. July 2002.

BI1182.52. Double-blind, randomized, dose optimization trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. May 2002.

AI424-045. A randomized, open label study of the antiviral efficacy and safety of atazanavir, in combination with ritonavir or saquinavir, and the combination of lopinavir each with tenofovir and a nucleoside in subjects who have experienced virologic failure. Bristol-Myers Squibb. Investigator April 2002.

CNA30021. A phase III, 48 week, randomised, double-blind, multicentre study to evaluate the safety and efficacy of abacavir (ABC) 600mg once-daily(QD) vs abacavir 300mg BID in combination with lamivudine (3TC) (300mg QD) and efavirenz (EFV) (600mg QD) in antiretroviral therapy Naïve HIV-1 infected subjects. GlaxoSmithKline. Investigator November 2001.

HIV-TE-Evaluation Project 101. An Evaluation of the Use of the HIV-Therapy Edge (HIV-TE) Service in the Management of HIV-Positive Patients Currently Failing Antiretroviral Drug Therapy. Intelligent Therapeutic Solutions, Inc. Investigator May 2001.

ESS40013. A Phase IV Multicenter Study of the Efficacy and Safety Of 48-Week Induction Treatment with Trizivir + Efavirenz Followed by 48-Week Randomized, Open-Label Maintenance Treatment with Trizivir ± Efavirenz in HIV-1 Infected ART Naïve Subjects. GlaxoSmithKline. Investigator Mar 2001.

AI455-110. A Study to Compare Stavudine (D4T) Extended Release (ER) versus Conventional (Immediate Release, IR) Formulations, Each in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Subjects who have Completed BMS Studies AI455-096 and AI455-099. Bristol-Myers Squibb. Investigator Jan 2001.

## **CURRICULUM VITAE**

Brian Onbirbak, MD

Page 5

Protocol ESS 40001 A Phase IV, open-label, randomized study to compare the efficacy and safety of Efavirenz/Zidovudine/Zalcitabine versus Efavirenz/Zidovudine/Sustiva versus Efavirenz/Zidovudine/Abacavir/Norvir for 96 weeks in the treatment of HIV-1 infected subjects who are Antiretroviral therapy naive. Glaxo Wellcome. Investigator, Aug 2000.

Protocol ESS 40009 Ziagen Optimal Regimen and Resistance Observational Study. A Phase IV, Open-label study to assess the safety and tolerability of abacavir (Ziagen), in HIV-1 infected individuals and to investigate the effect of baseline genotype with virtual phenotype on the response to abacavir (Ziagen) in therapy experienced subjects in the clinical setting. GlaxoWellcome Research and Development, Co-Investigator, Aug 2000.

Protocol M99-046. ABT-378/r (ABT-378/ritonavir) Early Access Program. Co-investigator, Abbott Laboratories, Jan 2000.

Co-investigator, Evaluation of the safety and antiviral activity of stavudine extended release formulation as compared to stavudine immediate release formulation, each as part of potent antiretroviral combination therapy. (AI455-096), Co-investigator, Bristol-Myers Squibb, Oct 1999.

Evaluation of the safety and antiviral activity of Stavudine Extended Release formulation as compared to Stavudine Immediate Release formulation, each as part of potent antiretroviral combination therapy. (AI45-096), Bristol-Myers Squibb, Oct 1999.

Co-Investigator, A Phase III trial to determine efficacy of bivalent AIDSVAX B/B vaccine in adults at risk for sexually transmitted HIV-1 infection in North America (VAX004), Vaxgen, Inc., March, 1999.

Co-Investigator, Amprenavir (141W94), Open label protocol for patients with HIV-1 infection who have experienced treatment failure or are intolerant to protease inhibitor therapy, (PR030010), Glaxo-Wellcome, Dec, 1998.

Co-Investigator, The Thalidomide Compassionate Use Program. Compassionate Use of Thalidomide in Adults with HIV-Associated Wasting (W-002), Celgene Corp. (1998).

Co-Investigator, An Open-Label Multicenter Study to Assess the Safety and Antiviral Activity of Twice-Daily Dosing Regimen of Viracept Combined with Two Reverse Transcriptase Inhibitors in HIV-Infected, Treatment Naïve Patients (AG13543-1022), Agouron Pharmaceuticals, 1998.

Co-investigator, A Multicenter Open Label Randomized 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate 800mg Q8H Versus 1200mg Q12H in HIV-Infected Individuals Having Plasma Viral RNA Less than 400 copies/ml on Concomitant Therapy with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (076-00), Merck & Co.

Principal Investigator, Protocol DMP 266-006, A Phase III Protocol to evaluate DMP-266 in combination with Indinavir, or DMP-266 +ZDV+3TC, or Indinavir +ZDV+ 3TC in HIV Infected Patients, Dupont Pharmaceuticals, 1998.

## **CURRICULUM VITAE**

Brian Onbirbak, MD

Page 6

Co-Investigator, Preveon Expanded Access Program for the Treatment of Patients with AIDS Who Have Failed Other Antiretroviral Therapy and have Limited Treatment Options. GS-52-427, Gilead Sciences, 1998.

Co-Investigator, Sustiva (Efavirenz) Expanded Access Program DMP266-903 (IND# 49,465), Dupont Merck, 1998.

Principal Investigator, Protocols NRI5520 and NRI5539, A Phase IIIB Open-Label Protocol to Evaluate Saquinavir Soft Gel Treatment in Combination with Other Antiretrovirals in HIV-Positive Patients, Hoffman-La Roche Ltd., 1997.

Principal Investigator, Expanded Access Program 1592U89 (Abacavir), Glaxo-Wellcome, Inc., 1997.

Principal Investigator, Viracept (AG134-515) Expanded Access Program (Ind. 48.124), Agouron Pharmaceuticals, Inc., 1997.

Principal Investigator, Protocol PR95-29-015, A 16 week, Open Label Study in Anemic HIV Infected Patients Who are Receiving AZT Either Alone or in Combination with Other Antiretroviral Agents, to determine the Effectiveness of Procrit in Alleviating Anemia and Improving the Quality of Life, 1996.

Principal Investigator, CTN 087287-003, "An Open Label Randomized Pharmacodynamic Study of Mycobutin (Rifabutin) Monotherapy, or Mycobutin in Combination with Myambutol (Ethambutol), for prophylaxis of Mycobacterium-avium Complex (MAC) Bacteremia in AIDS Patients with CD4 Counts <100", 1996.

Co-investigator, Indinavir (Crixivan) A Noncomparative, Multisite, Open-label, 48 week Study to Monitor the Safety and Tolerability of MK-0639 (Indinavir Sulfate) 800mg every 8 hours Administered as Monotherapy or in Combination with Reverse Transcriptase Inhibitor Therapy for Treatment of HIV-1 Infection in Advanced AIDS Patients, 99-00, Merck and Co., Inc., 1996.

Principal Investigator, 3TC (Lamivudine) Open Label Program; Protocol NUCA 3004; Glaxo-Wellcome, Inc., 1995.

Principal Investigator, Continuation protocols with open label Saquinavir (Ro 31-8959) for HIV-infected patients who have completed a clinical Trial with Saquinavir treatment; protocol SV 14788, Hoffman-LaRoche Limited, 1995

Co-investigator, Vistide (Cidofovir) intravenous Treatment IND Protocol For relapsing Cytomegalovirus retinitis in patients with AIDS; Protocol GS-95120; Gilead Science, 1995.

Principal Investigator, Saquinavir Phase III Clinical Trials, Protocol SVI4604C; Hoffman-LaRoche Limited, December 1994.

## **CURRICULUM VITAE**

Brian Onbirbak, MD

Page 7

Co-Investigator, Azithromycin/CP-62, 993 Phase R protocol "Oral/intravenous Azithromycin treatment of Cryptosporidiosis in patients whose disease has not been controlled by conventional therapy" Protocol 066-167S, Premier Research, 1994.

Seggev JS, Hamilton RG, Onbirbak BB. Abstract: "Latex and Glove Powder Sensitivity among Health Care Workers". *Annals of Allergy*, January 1994; 72 (1): 53.

## **PERSONAL**

Date of Birth: June 11, 1964

Citizenship: USA

Languages: Spanish and Persian (Farsi)